Geneset Name#,¶ | N Genes+ | Direction§ | two-sided directional | non-directional | ||
p-valueƒ | FDR## | p-valueƒ | FDR## | |||
HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | 13 | Up | 6.92 | 2.74 | 2.61 | 6.92 |
HALLMARK_COMPLEMENT | 76 | Up | 6.60 | 23.44 | 21.74 | 6.60 |
HALLMARK_KRAS_SIGNALING_DN | 40 | Down | 6.60 | 11.03 | 10.67 | 6.60 |
HALLMARK_IL6_JAK_STAT3_SIGNALING | 73 | Up | 6.46 | 19.71 | 18.62 | 6.46 |
HALLMARK_UNFOLDED_PROTEIN_RESPONSE | 16 | Up | 6.37 | 2.47 | 2.35 | 6.37 |
HALLMARK_APOPTOSIS | 79 | Up | 6.37 | 17.81 | 17.02 | 6.37 |
HALLMARK_OXIDATIVE_PHOSPHORYLATION | 33 | Up | 5.25 | 5.28 | 5.05 | 5.25 |
HALLMARK_P53_PATHWAY | 56 | Up | 4.98 | 16.44 | 15.69 | 4.98 |
HALLMARK_MTORC1_SIGNALING | 47 | Up | 4.84 | 12.27 | 11.85 | 4.84 |
HALLMARK_INTERFERON_GAMMA_RESPONSE | 110 | Up | 4.84 | 13.77 | 13.25 | 4.84 |
HALLMARK_PROTEIN_SECRETION | 10 | Up | 4.78 | 1.14 | 1.11 | 4.78 |
HALLMARK_GLYCOLYSIS | 48 | Up | 4.75 | 14.00 | 13.44 | 4.75 |
HALLMARK_PANCREAS_BETA_CELLS | 5 | Down | 4.59 | 0.09 | 0.09 | 4.59 |
HALLMARK_HYPOXIA | 60 | Up | 4.55 | 18.84 | 17.84 | 4.55 |
HALLMARK_MYC_TARGETS_V2 | 8 | Up | 4.49 | 0.25 | 0.24 | 4.49 |
HALLMARK_CHOLESTEROL_HOMEOSTASIS | 15 | Up | 4.33 | 1.83 | 1.77 | 4.33 |
HALLMARK_INTERFERON_ALPHA_RESPONSE | 52 | Up | 4.33 | 8.74 | 8.41 | 4.33 |
HALLMARK_SPERMATOGENESIS | 19 | Down | 3.68 | 1.59 | 1.54 | 3.68 |
HALLMARK_MYC_TARGETS_V1 | 28 | Up | 3.60 | 4.40 | 4.22 | 3.60 |
HALLMARK_KRAS_SIGNALING_UP | 77 | Up | 3.38 | 16.13 | 15.43 | 3.38 |
HALLMARK_ADIPOGENESIS | 30 | Up | 3.30 | 4.88 | 4.67 | 3.30 |
HALLMARK_COAGULATION | 56 | Up | 3.05 | 15.14 | 14.49 | 3.05 |
HALLMARK_XENOBIOTIC_METABOLISM | 36 | Up | 2.98 | 11.63 | 11.25 | 2.98 |
HALLMARK_ANDROGEN_RESPONSE | 16 | Up | 2.86 | 2.24 | 2.14 | 2.86 |
HALLMARK_FATTY_ACID_METABOLISM | 20 | Up | 2.79 | 4.63 | 4.44 | 2.79 |
HALLMARK_APICAL_JUNCTION | 61 | Up | 2.69 | 18.58 | 17.70 | 2.69 |
HALLMARK_UV_RESPONSE_UP | 46 | Up | 2.68 | 12.07 | 11.67 | 2.68 |
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION | 81 | Up | 2.64 | 14.94 | 14.32 | 2.64 |
HALLMARK_ESTROGEN_RESPONSE_EARLY | 40 | Up | 2.60 | 8.46 | 8.16 | 2.60 |
HALLMARK_TGF_BETA_SIGNALING | 20 | Up | 2.53 | 3.35 | 3.20 | 2.53 |
HALLMARK_ESTROGEN_RESPONSE_LATE | 51 | Up | 2.51 | 12.47 | 12.01 | 2.51 |
HALLMARK_DNA_REPAIR | 27 | Up | 1.99 | 5.96 | 5.71 | 1.99 |
HALLMARK_MITOTIC_SPINDLE | 27 | Up | 1.94 | 3.12 | 2.98 | 1.94 |
HALLMARK_IL2_STAT5_SIGNALING | 85 | Up | 1.81 | 14.68 | 14.10 | 1.81 |
HALLMARK_ANGIOGENESIS | 19 | Up | 1.81 | 2.23 | 2.13 | 1.81 |
HALLMARK_UV_RESPONSE_DN | 44 | Up | 1.78 | 8.73 | 8.41 | 1.78 |
HALLMARK_HEDGEHOG_SIGNALING | 12 | Up | 1.75 | 0.98 | 0.96 | 1.75 |
HALLMARK_G2M_CHECKPOINT | 67 | Up | 1.70 | 12.43 | 11.99 | 1.70 |
HALLMARK_APICAL_SURFACE | 13 | Up | 1.68 | 1.32 | 1.28 | 1.68 |
HALLMARK_TNFA_SIGNALING_VIA_NFKB | 107 | Up | 1.57 | 13.21 | 12.71 | 1.57 |
HALLMARK_INFLAMMATORY_RESPONSE | 115 | Up | 1.49 | 20.51 | 19.29 | 1.49 |
HALLMARK_E2F_TARGETS | 61 | Up | 1.46 | 8.04 | 7.76 | 1.46 |
HALLMARK_NOTCH_SIGNALING | 21 | Up | 1.26 | 3.71 | 3.54 | 1.26 |
HALLMARK_MYOGENESIS | 35 | Up | 1.11 | 7.37 | 7.11 | 1.11 |
HALLMARK_PI3K_AKT_MTOR_SIGNALING | 56 | Up | 1.11 | 18.55 | 17.70 | 1.11 |
HALLMARK_PEROXISOME | 17 | Up | 0.80 | 2.12 | 2.04 | 0.80 |
HALLMARK_ALLOGRAFT_REJECTION | 141 | Up | 0.42 | 22.32 | 20.92 | 0.42 |
HALLMARK_WNT_BETA_CATENIN_SIGNALING | 27 | Up | 0.38 | 5.58 | 5.34 | 0.38 |
HALLMARK_BILE_ACID_METABOLISM | 14 | Down | 0.25 | 1.79 | 1.73 | 0.25 |
HALLMARK_HEME_METABOLISM | 19 | Up | 0.04 | 2.19 | 2.10 | 0.04 |
All p-value and FDR reported as −log10 value.
#Geneset signatures in green are enriched in SARS-CoV-2 compared to control (i.e. Direction is Up) while red is the opposite direction (i.e. Down);
¶Genesets highlighted in yellow indicates biological processed upregulated in SARS-CoV-2 infected lungs. List ordered by descending FDR;
+N-Genes, number of genes in the geneset;
§Direction, direction of change (i.e. up or down);
ƒp-value, statistical significance of the difference;
##FDR, false discovery rate.